Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...
What to Expect From an Antibody-Drug Conjugate for HR+/HER2- Metastatic ... The Consumer’s Guide to JAK Inhibitors for Ankylosing Spondylitis JAK inhibitors are the newest, most targeted FDA ...